替吉奥与卡培他滨同步放疗用于结肠癌根治术后复发患者的效果比较

Clinical Observation of Tegafur Gimeracil and Oteracil Potassium and Capecitabine Synchronous Radiotherapy in the Treatment of Recurrence after Radical Resection of Colon Cancer

目的:比较卡培他滨与替吉奥同步三维适形放疗用于结肠癌根治术后复发患者的临床疗效及安全性。方法:选取我院2010年1月-2012年12月收治的结肠癌根治术后复发患者150例,按照随机数字表法分为A、B组,各75例。两组患者均行三维适形放疗,A组患者同步加服卡培他滨片2.5 g;而B组患者则同步加服替吉奥胶囊,体表面积<1.25 m^2给予40 mg,bid,体表面积1.25~1.50 m2给予50 mg,bid,体表面积>1.50 m2给予60 mg,bid。比较两组患者临床疗效,随访1、2、3年生存情况及Ⅲ~Ⅳ级药物毒副作用发生率。结果:B组患者临床总有效率为86.67%,显著高于A组的66.67%,差异有统计学意义(P<0.05);B组患者随访1、2、3年生存率分别为93.33%、72.00%、58.67%,显著高于对照组的74.67%、53.33%、41.33%,差异均有统计学意义(P<0.05);A组患者中位疾病进展时间为8.0个月,显著短于B组的9.5个月,差异有统计学意义(P<0.05)。两组患者Ⅲ~Ⅳ级药物毒副作用发生率比较,差异无统计学意义(P>0.05)。结论:替吉奥同步辅助三维适形放疗用于结肠癌根治术后复发患者较卡培他滨疗效显著,可有效控制病情进展,延长生存时间,且未增加毒副作用发生风险。

OBJECTIVE： To observe clinical efficacy and safety of capecitabine and tegafur gimeracil and oteracil potassium synchronous radiotherapy in the treatment of recurrence after radical resection of colon cancer. METHODS： A total of 150 patients with recurrent after radical resection of colon cancer in our hospital during Jan. 2012-Dec. 2012 were divided into group A and B ac- cording to random number table, with 75 cases in each group. Both groups received three-dimensional conformal radiotherapy. Group A was additionally given capecitabine 2.5 g. Group B was additionally given tegafur gimeracil and oteracil potassium, 40 rag,bid for body surface area 〈1.25 m^2, 50 rag,bid for body surface area ranged 1.25-1.50 ms and60mg,bid for body surface ar- ea 〈 1.50 m^2. Clinical efficacies of 2 groups were compared; 1-year, 2-year, 3-year survival and Ill-IV degree toxic effect were fol- lowed up. RESULTS： The total response rate of group B was 86.67%, which was significantly higher than 66.67% of group A, with statistical significance（P〈0.05）. 1-year, 2-year, 3-year survival rates of group B were 93.335, 72.00%, 58.67%, which was significantly higher than 74.67%, 53.33%, 41.33%, with statistical significance （P〈0.05）. The median disease progression time of group A was 8.0 months, which was significantly shorter than 9.5 months of group B, with statistical significance （P〈0.05）. There was no statistical significance in Ⅲ-Ⅳ degree toxic effect between 2 groups （P〈0.05）. CONCLUSIONS： Compared with capecitabine, tegafur gimeracil and oteracil potassium combined with three-dimensional conformal radiotherapy show significant therapeutic efficacy for recurrence after radical resection of colon cancer, can control disease progression, prolong the survival time and don＇t increase the risk of toxic effects.